logo-loader
Q BioMed Inc

QBioMed appoints Yale psychologist to advisory committee

Dr Pamela Ventola works at Yale University’s Child Study Center where she focuses on behavioral treatments for autism

empty board room
Q BioMed’s drug QBM-001 is being developed for the treatment of autistic children

Q BioMed Inc (OTCQB:QBIO), the New York biotech, announced Wednesday that Dr. Pamela Ventola of Yale University has joined its advisory committee for its QBM-001 clinical program, which is advancing its drug treatment for autistic toddlers.

Dr Ventola now works as a clinical psychologist and assistant professor at Yale University’s Child Study Center where she focuses on behavioral treatments for autism spectrum disorders.

READ: Q BioMed partners with SRI International for autism drug QBM-001

A licensed clinical psychologist, Dr. Ventola is an expert in pediatric neuropsychology and developmental disabilities. She also holds the position of senior science director at the Rare Disease and Pediatric Center of Excellence at Cogstate, a company that supports pharmaceutical companies in clinical trial design.

“Children with [autism spectrum disorders] need safe, effective and targeted treatments that are tested under conditions that take their best interests into consideration to ensure a successful trial,” said Dr. Ventola in a statement. “I am inspired that Q BioMed has the same vision and am excited to ensure QBM-001 has the best chance to help their targeted subgroup.”

Denis Corin, CEO of QBioMed, says Ventola’s expertise will prove helpful as QBioMed prepares its investigational new drug application for QBM-001 to submit to the US Food and Drug Administration.

“[Ventola] is a leader in clinical trial design and biomarker research for the autism spectrum, which is a perfect fit for the subgroup Q BioMed is targeting,” Corin said. “Dr. Ventola will be an asset to our development program as we prepare our Investigational New Drug Application (IND) for submission to the FDA in this important indication for which no drugs are currently available.”

Q BioMed’s drug treatment QBM-001 is being developed and tested for the treatment of minimally verbal and non-verbal toddlers with an autism spectrum disorder.

Contact Ellen Kelleher at [email protected]

Quick facts: Q BioMed Inc

Price: $1.05

Market: OTCQB
Market Cap: $15.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed successfully synthesizes molecule to treat liver...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer. Corin says the molecule called...

1 hour, 13 minutes ago

2 min read